Finnian R Mc Causland1, Brian Claggett2, Emmanuel A Burdmann3, Glenn M Chertow4, Mark E Cooper5, Kai-Uwe Eckardt6, Peter Ivanovich7, Andrew S Levey8, Eldrin F Lewis2, Janet B McGill9, John J V McMurray10, Patrick Parfrey11, Hans-Henrik Parving12, Giuseppe Remuzzi13, Ajay K Singh14, Scott D Solomon2, Robert D Toto15, Marc A Pfeffer2. 1. Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: fmccausland@partners.org. 2. Harvard Medical School, Boston, MA; Cardiology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 3. Division of Nephrology, University of Sao Paulo Medical School, Sao Paulo, Brazil. 4. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA. 5. Monash University Central Clinical School, Melbourne, VIC, Australia. 6. Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany. 7. Renal Division, Northwestern University, Chicago, IL. 8. Division of Nephrology, Tufts Medical Center, Boston, MA. 9. Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, MO. 10. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland. 11. Health Sciences Centre, Memorial University of Newfoundland, St. John's, Newfoundland, Canada. 12. Department of Medical Endocrinology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 13. IRCCS-Istituto di Ricerche Farmacologiche Mario Negri; Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. 14. Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. 15. Renal Division, University of Texas Southwestern, Dallas, TX.
Abstract
RATIONALE & OBJECTIVE: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes. STUDY DESIGN: Post hoc analysis of a randomized controlled trial. SETTING & PARTICIPANTS: Participants with type 2 diabetes and chronic kidney disease who progressed to dialysis therapy (n=590) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). EXPOSURE: Randomized treatment assignment (darbepoetin vs placebo). OUTCOMES: All-cause mortality, CV mortality, nonfatal myocardial infarction, heart failure, and stroke within the first 180 days of dialysis therapy initiation. ANALYTICAL APPROACH: Proportional hazards regression. RESULTS: Overall, 590 of 4,038 (14.6%) participants initiated dialysis therapy during the trial (n=298 and 292 in the darbepoetin and placebo groups, respectively). Corresponding hemoglobin levels were 11.3±1.6 and 9.5±1.5g/dL (P<0.001). Death from any cause occurred in 31 (10.4%) participants assigned to darbepoetin and 28 (9.6%) assigned to placebo (HR, 1.16; 95% CI, 0.69-1.93), while death from CV causes occurred in 15 (5.0%) and 13 (4.5%) participants, respectively (HR, 1.21; 95% CI, 0.58-1.93). There were no differences in risk for nonfatal myocardial infarction or heart failure. Stroke occurred in 8 (2.8%) participants assigned to darbepoetin and 1 (0.3%) assigned to placebo (HR, 8.6; 95% CI, 1.1-68.7). LIMITATIONS: Post hoc analyses of a subgroup of study participants. CONCLUSIONS: Despite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.
RCT Entities:
RATIONALE & OBJECTIVE: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes. STUDY DESIGN: Post hoc analysis of a randomized controlled trial. SETTING & PARTICIPANTS: Participants with type 2 diabetes and chronic kidney disease who progressed to dialysis therapy (n=590) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). EXPOSURE: Randomized treatment assignment (darbepoetin vs placebo). OUTCOMES: All-cause mortality, CV mortality, nonfatal myocardial infarction, heart failure, and stroke within the first 180 days of dialysis therapy initiation. ANALYTICAL APPROACH: Proportional hazards regression. RESULTS: Overall, 590 of 4,038 (14.6%) participants initiated dialysis therapy during the trial (n=298 and 292 in the darbepoetin and placebo groups, respectively). Corresponding hemoglobin levels were 11.3±1.6 and 9.5±1.5g/dL (P<0.001). Death from any cause occurred in 31 (10.4%) participants assigned to darbepoetin and 28 (9.6%) assigned to placebo (HR, 1.16; 95% CI, 0.69-1.93), while death from CV causes occurred in 15 (5.0%) and 13 (4.5%) participants, respectively (HR, 1.21; 95% CI, 0.58-1.93). There were no differences in risk for nonfatal myocardial infarction or heart failure. Stroke occurred in 8 (2.8%) participants assigned to darbepoetin and 1 (0.3%) assigned to placebo (HR, 8.6; 95% CI, 1.1-68.7). LIMITATIONS: Post hoc analyses of a subgroup of study participants. CONCLUSIONS: Despite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.
Authors: Angelo Karaboyas; Hal Morgenstern; Sandra Waechter; Nancy L Fleischer; Raymond Vanholder; Stefan H Jacobson; Manish M Sood; Douglas E Schaubel; Masaaki Inaba; Ronald L Pisoni; Bruce M Robinson Journal: Clin Kidney J Date: 2019-07-05
Authors: Marcelo Barreto Lopes; Charlotte Tu; Jarcy Zee; Murilo Guedes; Ronald L Pisoni; Bruce M Robinson; Bryce Foote; Katarina Hedman; Glen James; Antonio Alberto Lopes; Ziad Massy; Helmut Reichel; James Sloand; Sandra Waechter; Michelle M Y Wong; Roberto Pecoits-Filho Journal: Sci Rep Date: 2021-01-19 Impact factor: 4.379
Authors: Lois Lamerato; Glen James; Heleen van Haalen; Katarina Hedman; James A Sloand; Amy Tang; Eric T Wittbrodt; Jerry Yee Journal: BMC Nephrol Date: 2022-04-30 Impact factor: 2.585
Authors: Gunnar Toft; Uffe Heide-Jørgensen; Heleen van Haalen; Glen James; Katarina Hedman; Henrik Birn; Christian F Christiansen; Reimar W Thomsen Journal: J Nephrol Date: 2019-10-05 Impact factor: 3.902